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Telomerase reactivation is a hallmark of human carcinogenesis. Increased telomerase activity may result from gene amplification
and/or overexpression. This study evaluates the prognostic value of hTERT gene amplification and mRNA overexpression in 144
resectable non-small-cell lung cancer (NSCLC) specimens. The hTERT gene copy number was assessed by quantitative polymerase
chain reaction (qPCR) on laser-capture microdissected tumour cells of 81 tumours, and by fluorescence in situ hybridisation (FISH) on
a subset of 59 tumours. hTERT mRNA level was determined by reverse transcription (RT)–qPCR in 130 tumours. In total, 57% of (46
out of 81) primary NSCLC specimens demonstrated hTERT amplification, which was significantly more common (Po0.001) in
adenocarcinoma (30 out of 40) than in squamous cell carcinoma (13 out of 37). The hTERT mRNA overexpression was noted in 74%
(94 out of 130) of tumours; it was more frequent in squamous cell than in adenocarcinoma (87 vs 68%, P¼0.03). Overexpression
was significantly associated with amplification (P¼0.03), especially in adenocarcinoma. The hTERT gene amplification was prognostic
for shorter recurrence-free survival (hazard ratio¼2.16, P¼0.03). These data indicate that gene amplification is an important
mechanism for hTERT overexpression in lung adenocarcinoma and is an independent poor prognostic marker for disease-free survival
in NSCLC.
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Telomerase is a ribonucleoprotein reverse transcriptase complex
containing an RNA subunit hTERC and a protein catalytic subunit
hTERT (Nakamura et al, 1997). The hTERC RNA is expressed
universally in eukaryotic cells and hTERT expression has been
correlated with activation of the telomerase complex (Nakamura
et al, 1997; Kolquist et al, 1998; Arinaga et al, 2000). Telomerase
activity is absent in most human adult somatic cells. With
continuous cell proliferation, there is a progressive loss of
telomeric DNA that ultimately may trigger replicative senescence.
The forced expression of hTERT cDNA in normal human cells has
led to extension of the replicative lifespan (Vaziri and Benchimol,
1998). An alternative mechanism for cellular immortalisation is
by the telomerase-independent ALT pathway (Newbold, 2002).
Activations of the hTERT or ALT pathways are obligate for
senescence bypass and for neoplastic transformation of normal
cells (Newbold, 2002). Telomerase activity and/or hTERT expres-
sion are increased in cancers and are prognostic factors in various
cancer types (Harada et al, 1999; Bieche et al, 2000; Lee et al, 2001;
Marchetti et al, 2002; Wang et al, 2002; Fujita et al, 2003; Krams
et al, 2003; Ohali et al, 2003; Tchirkov et al, 2003; Lantuejoul et al,
2004). However, the clinical impact of hTERT expression or
activity in non-small-cell lung cancer (NSCLC) remains contro-
versial (Albanell et al, 1997; Taga et al, 1999; Hirashima et al, 2000;
Komiya et al, 2000; Toomey et al, 2001; Marchetti et al, 2002; Wang
et al, 2002; Fujita et al, 2003; Wu et al, 2003; Hsu et al, 2004;
Lantuejoul et al, 2004). The clinical significance of increased
hTERT gene copy number has not been investigated.
Multiple mechanisms may regulate hTERT expression and
activity. There is considerable evidence that transcriptional
activation plays a major role in regulating hTERT mRNA
expression (Ducrest et al, 2002), and the latter is correlated with
telomerase activity (Arinaga et al, 2000; Marchetti et al, 2002;
Saretzki et al, 2002). However, post-translational modifications
may also contribute to the regulation of hTERT activity (Kang
et al, 1999). Increased expression of hTERT resulting from gene
amplification was recently reported in embryonal brain tumours
(Fan et al, 2003) and cervical carcinoma (Zhang et al, 2002). The
hTERT gene is located on chromosome 5p15, a chromosomal arm
that is commonly overepresented or amplified in lung cancer (Luk
et al, 2001). Amplification of the hTERT gene and a concomitant
increase in telomerase activity has been reported in lung cancer
cell lines and other cancer types (Zhang et al, 2000; Saretzki et al,
2002). In this study, we have investigated the frequency and
prognostic significance of hTERT gene amplification and over-
expression in NSCLC.
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sMATERIALS AND METHODS
Patients and clinical samples
Patients included in this study had undergone lobectomy or
pneumonectomy for resection of their primary lung cancer but
had not received prior radiation or chemotherapy. Altogether, 169
tissue samples from 144 patients were used; these included 144
tumours and a corresponding subset of 30 non-neoplastic lung
tissues. The latter were used to define the normal ranges for hTERT
mRNA expression levels and gene copy number. Tissues were
collected within 30min after resection, snap-frozen and stored in
liquid nitrogen until used; all were verified by histopathology. The
collection of tissue and clinical and follow-up data was carried out
in accordance with guidelines established by the Research Ethics
Board (REB) of the University Health Network (UHN), which also
approved this study.
DNA isolation and laser-captured microdissection
DNA was isolated from tumour cells micro-dissected using the
Arcturus Pixcell II (Mountain View, CA, USA) laser capture
microdissection (LCM) system. This includes 40 adenocarcinomas
(ADC), 37 squamous cell carcinomas (SQCC), three adenosqua-
mous carcinomas (ADSQC) and one large cell carcinoma (LCC). In
addition, DNA was also extracted from 19 non-neoplastic lung
samples. The tumour cells micro-dissected using LCM system were
incubated in DNA extraction buffer containing 50mM KCl, 10mM
Tris-HCl (pH 8.3), 0.1mgml
 1 gelatin, 0.45% Nonidet P-40, 0.45%
Tween 20 and 0.4mgml
 1 proteinase K. DNA was subsequently
extracted by the phenol–chloroform method (Zhu et al, 2004).
Quantitative polymerase chain reaction
The quantitative polymerase chain reaction (qPCR) was performed
using the SYBR Green technique in an ABI Prism 7700 sequence
Detection System (Applied Biosystem, Foster City, CA, USA). The
primer sequences were: hTERT sense 50-taa aat tat cca cat ggc tca
cgt-30, antisense 50-ctt ggg aac cag gac aaa gg-30; PIK3R1 sense 50-
atc tgc cac tgg ctt ccc tt-30, antisense 50-cag tct ttc cct gat cat tga
acc-30. The PCR conditions were optimized as reported (Zhu et al,
2004). The PIK3R1 (5q13.1) gene is used as the reference
nonamplified gene in NSCLC (Massion et al, 2002), and the
hTERT gene copy number was estimated using comparative CT
method. DNA from normal male lymphocyte (Novagen, San Diego,
CA, USA) was used as the reference DNA. With this method,
samples with normal copy number (disomy at both loci) or
balanced polysomy (increased but equal copy number of both the
reference and hTERT loci) will have an hTERT/PIK3R1 ratio of 1.
Copy number values above or below the 2 standard deviations
(s.d.) of mean of normal lung tissues values were designated as
amplified or loss of the hTERT gene copy. Tumours with hTERT
amount within the 2 s.d. of mean of normal lung tissues were
classified as showing nonamplified samples.
Fluorescence in situ hybridisation
Archival paraffin blocks of 59 tumours that had been studied by
qPCR were retrieved for fluorescence in situ hybridisation (FISH)
analysis. Sections (4mm) were mounted on positively charged
slides and baked flat for 12–16h at 561C. Slides were dewaxed in
three changes of xylene for 10min each, followed by two changes
in 100% ethanol for 5min each. After air-drying, slides were
treated in 2 SSC for 20min at 751C, then for 5min at room
temperature (RT). The sections were then treated with
0.25mgml
 1 proteinase K (Roche, Laval, QC, Canada) in 2 SSC
at 451C for 20min, followed by washing in 2  SSC at RT for 5min
and serial dehydration through 70, 90 and 100% ethanol, and then
left to air dry.
The hTERT/5q dual-colour FISH probe cocktail (Qbiogene,
Montreal, QC, Canada) was applied at 0.02–0.06mlmm
 2 and
sealed with rubber cement. The probe and target DNA were
codenatured by heating to 801C for 10min in a Hybrite slide
incubator (Vysis/Abbott Laboratories, Markham, ON, Canada).
Hybridisation was for 16–20h at 371C in a moist light-sealed
chamber in a dry oven. The slides were washed in two changes of
2 SSC with 0.1% SDS at 451C for 5min each, followed by 5min in
2 SSC at RT. Slides were partially air-dried and 20–30ml of DAPI
mounting medium with antifade (Vector Labs, Burlingame, CA,
USA) was applied, then cover slipped without sealing. Slides were
stored in the dark at  201C prior to imaging.
The FISH images were captured using the AxioImager system
(Zeiss, Go ¨ttingen, Germany) with Z-stacking capabilities. Tumour
cell nuclei identified using a DAPI filter and Z-stacked three-
channel colour images (DAPI, FITC and Rhodamine/Cy3) were
captured at  63 or  100 under oil immersion. Intact,
nonoverlapping tumour cell nuclei (minimum 50 per case) without
juxtaposed FISH signals were scored for the number of green
(5p15.33) hTERT locus and red (5q31) control signals. The
surrounding nontumour cells provide baseline estimation of the
normal FISH signals (two green and two red signals). For survival
analysis, high gene copy number cases included tumours with high
polysomy (X4h TERT gene copy in more than 40% of the tumour
cells) or amplification (presence of tight hTERT gene clusters and a
ratio of hTERT to chromosome of X2o rX15 copies of gene per
cell in X10% of analysed tumour cells), as defined by Cappuzzo
et al (2005) for their study of the role of epidermal growth factor
receptor (EGFR) gene copy number in EGFR inhibitor therapy.
Reverse transcription–qPCR
The mRNA expression was assayed using reverse transcription
(RT)–qPCR on total RNA of 130 primary NSCLC and 18
corresponding non-neoplastic lung tissues using the ABI PRISM
7700 Sequence Detection System (Zhu et al, 2004). Total cellular
RNA was isolated from the frozen tissues, as previously described
(Tsao et al, 1998) and purified by the RNeasy Mini kit (Qiagen Inc.,
Mississauga, ON, Canada). The quality of the RNA preparations
was confirmed by the Agilent Bioanalyzer (Agilent Technologies,
Palo Alto, CA, USA). In total, 5mg of RNA was reverse transcribed
using the Taqman reverse transcription reagent (Applied Biosys-
tems, Branchburg, NJ, USA) in 100ml reaction solution according
to the manufacturer’s instruction. After appropriate dilution,
duplicate of 10ng of cDNA was used as template for qPCR analysis
of each sample. Primers were designed to span two adjacent exons
to avoid amplification of contaminating genomic DNA sequences.
The primers for hTERT were: sense 50-cgtcgagctgctcaggtctt-30,
antisense 50-agt gctgtctgattccaatgctt-30. The DCT method was used
to normalize the sample-to-sample variation in RNA/cDNA
quantity using the 18s ribosomal RNA as the housekeeping gene
(Zhu et al, 2004).
Statistical analysis
The Spearman correlation, w
2 tests or Fisher’s exact test were used
appropriately to assess association within and between molecular
indices and the pathological or clinical factors. The end points for
analyses were overall survival (from date of surgery to date of
death) and recurrence-free survival (from date of surgery to date of
recurrence). Cox proportional hazards regression was used in
univariate and multivariate analyses. For Kaplan–Meier analysis,
gene copy number and mRNA expression level were dichotomized
using the upper limits of 95% confidence interval (95% CI)
(meanþ2 s.d.) for normal samples into nonamplified vs amplified
or normal expression vs overexpression groups. Kaplan–Meier
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differences were determined by the log-rank test.
RESULTS
Patient characteristics
Table 1 shows the demographics of patients in the studies of
hTERT gene copy assessment by qPCR (n¼81) or FISH (n¼59),
and hTERT mRNA expression (n¼130) by RT–qPCR. There were
no significant differences in the age, gender, stage and tumour
differentiation grade among the three groups, but the mRNA
expression study included more ADC patients. More than 90%
of patients were stage I–II. The median follow-up was 3.19 (0.24–
7.93) years, and 11 patients died without a relapse.
hTERT gene amplification
Figure 1A shows the distribution of relative gene copy of hTERT in
normal and NSCLC. Using the upper limit of 95% CI (meanþ2
s.d.) for normal samples as cutoff, hTERT gene amplification was
found in 57% (46 of 81) of NSCLC patients. Gene copy loss was not
observed. Amplification was more common in ADC compared to
SQCC (Figure 1A), but was not correlated with tumour stage or
differentiation grade (Table 2). The Kaplan–Meier survival
estimation showed that patients with hTERT amplification by
qPCR had poorer recurrence-free survival (log rank test P¼0.02,
Figure 2A). An analysis using 2 mean of normalþ2 s.d. as the
cutoff to identify highly amplified patients showed statistically not
significant separation of the survival curves of amplified vs
unamplified patients, but further analysis showed that patients
with gene copy changes between Xmean of normalþ2 s.d. and
o2 mean of normalþ2 s.d. showed similar survival outcome as
the highly amplified (Xmean of normalþ2 s.d.) group, indicating
that low amplification patients also experienced poorer survival
outcome (Supplementary Figure 1). A similar trend of poorer
overall survival for patients with amplified hTERT gene was noted,
but this did not reach significance (log rank test P¼0.15,
Figure 2B).
Cox proportional hazards regression also showed a significant
association of hTERT amplification with increased risk for death
from recurrence (hazard ratio (HR) 2.16, 95% CI 1.07–4.37;
P¼0.03), but the correlation with poorer overall survival did not
reach significance (HR 1.70, 95%CI 0.82–3.52; P¼0.16). The
hTERT amplification remained a significant prognostic marker for
shorter recurrence-free survival (HR 2.06, 95%CI 1.01–4.2;
P¼0.05) after adjusting for the patient age, tumour stage and
differentiation grade.
Table 1 Clinical–pathological characteristics of patients in various
molecular studies
Gene copy
by qPCR
(n¼81) (%)
Gene copy
by FISH
(n¼59) (%)
mRNA
expression
(n¼130) (%) P- value
Age
Mean 69.0 69.9 68.8 0.73
Range (43.7–85.4) (43.7–85.4) (43.7–85.4)
Gender
Male 50 (61) 35 (59) 74 (57) 0.79
Female 31 (39) 24 (41) 56 (43)
Smoking history
Smoker 59 (73) 41 (69) 92 (71) 0.99
Nonsmoker 19 (23) 16 (27) 33 (25)
Unknown 3 (4) 2 (4) 5 (4)
Pathological
stage
Stage I 52(64) 42 (71) 91 (70) 0.90
Stage II 21 (26) 12 (20) 28 (22)
Stage III 8 (10) 5 (8) 11 (8)
T stage
T1 24 (30) 20 (34) 47 (36) 0.62
T2 54 (66) 37 (63) 82 (63)
T3 3 (4) 2 (3) 1 (1)
N stage
N0 53 (65) 43 (73) 90 (69) 0.92
N1 20 (25) 11 (19) 28 (22)
N2 8 (10) 5 (8) 12 (9)
Histology
ADC 40 (49) 32 (54) 83 (64) 0.03
SQCC 37 (46) 26 (44) 38 (29)
Other 4 (5) 1 (2) 9 (7)
Differentiation
grade
WD 20 (25) 16 (27) 33 (25) 0.98
MD 30 (37) 19 (32) 44 (34)
PD 31 (38) 24 (41) 53 (41)
The P-values were calculated using the w
2 test. ADC¼adenocarcinoma;
SQCC¼squamous cell carcinoma; WD¼well differentiated; MD¼moderately
differentiated; PD¼poorly differentiated; qPCR¼quantitative polymerase chain
reaction; FISH¼fluorescence in situ hybridisation.
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Figure 1 The distribution of hTERT gene copy number and mRNA
expression levels according to tissue and tumour type. N, normal lung
tissue; ADC, adenocarcinoma, SQCC, squamous cell carcinoma; LCC,
large-cell lung carcinoma.
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lost to follow-up at greater than 3 years after surgery, the 3-year
survival rates were also estimated (Table 3). hTERT amplification
was significantly associated with poorer recurrence-free survival
(HR 2.96, 95% CI 1.27–6.90, P¼0.01) and overall survival (HR
2.04, 95% CI 0.89–4.66, P¼0.09) at 3 years. Multivariate analysis
Table 2 hTERT copy number, mRNA expression and pathological factors
Gene copy mRNA expression
Nonamplified (n¼35) (%) Amplified (n¼46) (%) P-value Normal expression (n¼36) (%) Overexpression (n¼94) (%) P-value
Pathological stage
I 26 (74) 26 (57) 0.11 28 (78) 62 (66) 0.02
II 5 (14) 16 (35) 2 (6) 26 (28)
III 4 (12) 4 (8) 6 (16) 6 (6)
T stage
T1 12 (34) 12 (26) 0.70 16 (44) 31 (33) 0.11
T2 22 (63) 32 (69) 19 (53) 63 (67)
T3 1 (3) 2 (6) 1 (3)
N stage
N0 26 (74) 27 (59) 0.17 28 (78) 62 (66) 0.01
N1 5 (14) 15 (33) 2 (6) 26 (28)
N2 4 (12) 4 (8) 6 (16) 6 (6)
Histology
ADC 10 (29) 30 (65) o0.001 27 (75) 56 (60) 0.03
SQCC 24 (69) 13 (28) 5 (14) 33 (35)
Other 1 (2) 3 (7) 4 (11) 5 (5)
Differentiation grade
WD 9 (26) 11 (24) 0.98 8 (22) 25 (27) 0.28
MD 13 (37) 17 (37) 16 (45) 28 (30)
PD 13 (37) 18 (39) 12 (33) 41 (43)
P-values were calculated by using w
2 test. ADC¼adenocarcinoma; SQCC¼squamous cell carcinoma; WD¼well differentiated; MD¼moderately differentiated; PD¼poorly
differentiated; qPCR¼quantitative polymerase chain reaction; FISH¼fluorescence in situ hybridisation.
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Figure 2 Kaplan–Meier survival plots. (A) Recurrence-free survival (RFS) according to hTERT gene copy. (B) Overall survival (OS) according to hTERT
gene copy. (C) RFS according to expression levels of hTERT mRNA expression levels. (D) Overall survival according to hTERT mRNA expression levels.
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confirmed that amplification was an independent prognostic
marker for recurrence-free survival (HR 2.97, 95% CI 1.26–6.99,
P¼0.01; Table 3).
Validation of qPCR data with FISH
Fluorescence in situ hybridisation was performed on 59 tumours
that had been studied for hTERT gene copy by qPCR (Figure 3).
The ratios between the hTERT (green probe) and 5q13 reference
gene locus D5S89 (red probe) signals were significantly correlated
with the qPCR ratios of hTERT/PIK3R1 gene content (Spearman
correlation coefficient r¼0.43, P¼0.0006). A better correlation
was found for ADC (r¼0.61, P¼0.0003) than for SQCC (r¼0.34,
P¼0.086). hTERT gene amplification by FISH was found in 73%
(43 out of 59) of tumours and there were significant correlations
between qPCR and FISH results for all tumours (P¼0.008, Table 4)
and for ADC (P¼0.004). Although patients with high hTERT gene
copy number (high polysomy and amplification) by FISH were
more likely to experience early recurrence compared to those with
lower gene copy numbers (low polysomy, trisomy or disomy), the
difference was not statistically significant (HR 1.51, 95% CI 0.61–
3.76, P¼0.37).
hTERT mRNA expression
Reverse transcription–qPCR did not detect hTERT mRNA
expression in several non-neoplastic lung samples; therefore, the
expression level of each sample was arbitrarily represented relative
to the median of the entire data set. We used the meanþ2 s.d. of
the non-neoplastic lung expression levels as the cutoff to
dichotomise tumours into hTERT normal expression and over-
expression groups. Overexpression occurred in 72% (94 out of
130) of NSCLC, but was significantly more frequent in SQCC (87%)
compared to ADC (68%) (Figure 1B and Table 2). Overexpression
was also associated with higher tumour stages (Table 2). Among
tumours with expression data, hTERT gene copy results by qPCR
were also available for 67 cases (Table 5). Overexpression
correlated with amplification (P¼0.03) but only among the ADC
(P¼0.05). There were only 54 tumours with both FISH and
expression results; high hTERT gene copy by FISH was not
correlated with mRNA overexpression (data not shown).
Table 3 Univariate and multivariate survival analyses at 3-year follow-up
Univariate Multivariate*
HR 95% CI P HR 95% CI P
Recurrence-free survival
Amplification 2.96 1.27–6.90 0.01 2.97 1.26–6.99 0.01
Overexpression 1.82 0.89–3.75 0.14 2.07 0.94–4.27 0.11
Overall survival
Amplification 2.04 0.89–4.66 0.09 1.97 0.85–4.55 0.13
Overexpression 2.00 0.94–4.27 0.03 2.29 1.06–4.96 0.04
*Multivariate analyses adjusted for stage, differentiation grade and age. HR¼hazard
ratio; CI¼confidence interval.
Figure 3 Representative fluorescent in situ hybridisation (FISH) images. (A) A tumour with diploid genotype showing most tumour cell nuclei containing
two green signals (hTERT, 5p15.33) and two red signals (control locus, 5q31). (B) A polysomy tumour showing several signals of both the hTERT and 5q; (C)
Tumour with high-level amplification with their nuclei containing 10–30 hTERT signals and two or more 5q signals.
Table 4 Correlation between gene copy by qPCR and by FISH
Gene copy changes
FISH
qPCR Nonamplified Amplified
a P-value
b
All 22 37
Nonamplified 13 9
c 0.008
Amplified 9 28
Adenocarcinoma
Nonamplified 6 1 0.004
Amplified 5 18
Squamous cell carcinoma
Nonamplified 7 7 0.5
Amplified 4 8
aAmplified tumours were those showing presence of tight hTERT gene clusters or
hTERT to chromosome ratio of X2, or X15 copies per cell in X10% of tumour cells,
as defined by Cappuzzo et al (2005).
bP-values calculated using the two-sided Fisher’s
exact test.
cOne case was a large-cell carcinoma. qPCR¼quantitative polymerase
chain reaction; FISH¼fluorescence in situ hybridisation.
Table 5 Correlation between gene copy increases by qPCR and hTERT
mRNA expression
Gene copy changes
Nonamplified Amplified P-value
a
All 27 40
Normal expression 9
b 4 0.03
Overexpression 18 36
Adenocarcinoma
Normal expression 4 4 0.05
Overexpression 4 24
Squamous cell carcinoma
Normal expression 4 0 0.12
Overexpression 14 12
aP-values calculated using the two-sided Fisher’s exact test.
bOne case was a large-cell
carcinoma. qPCR¼quantitative polymerase chain reaction.
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between hTERT mRNA overexpression with recurrence-free
survival or overall survival (log rank P¼0.24 and P¼0.13,
respectively, Figure 2C and D), but it was significant for reduced
overall survival at the 3-year follow-up time (log rank P¼0.03,
Table 3). Cox proportional hazards regression also showed that
overexpression was an independent prognostic marker for overall
survival at 3-year follow-up (HR 2.29, 95% CI 1.06–4.96, P¼0.04)
after adjusting for age, tumour stage and differentiation.
DISCUSSION
We have evaluated the clinical and pathological significance of
hTERT gene amplification and mRNA overexpression in NSCLC
patients who were treated primarily by surgical resection. The
hTERT gene amplification occurred in 57% of NSCLC, but this was
more common among ADC (75%) than SQCC (35%). Among ADC,
hTERT mRNA overexpression was significantly correlated with
gene amplification (P¼0.05). However, 87% (33 of 38) of SQCC
also showed overexpression. These findings suggest that amplifi-
cation is responsible for hTERT mRNA overexpression in a
majority of ADC, while epigenetic factors at the transcriptional or
post-transcriptional levels significantly affect hTERT expression.
Most importantly, we have demonstrated that hTERT amplifica-
tion is an independent prognostic marker for shorter recurrence-
free survival in NSCLC patients.
Although many studies have examined the prognostic signifi-
cance of hTERT mRNA/protein expression or activity in NSCLC
(Table 6), to our knowledge, this is the first study that examined
the prognostic value of hTERT gene amplification in lung cancer
patients. The hTERT gene amplification was common in cell lines
and primary tumours of lung, cervix, breast and in neuroblastoma
(Zhang et al, 2000). Using X5 copies of hTERT gene copy per
nucleus in at least 20% of the cells to define amplification, Zhang
et al (2000) reported hTERT amplification in 38% (eight out of 21)
of lung carcinomas. Using qPCR that defines amplification as
tumours with hTERT gene content greater than that of PIK3R1
(5q13.1), we found amplification in 57% of NSCLC. We also found
a significant concordance between hTERT gene copy number
assayed by qPCR and FISH (Spearman correlation coefficient
r¼0.43, P¼0.0006), indicating that qPCR may serve as an
alternative method to assay amplification.
There are some differences in the results of qPCR and FISH
analyses on tumours. The qPCR assay cannot, whereas FISH can
distinguish balanced copy gains (trisomy or polysomy) from
diploid. To identify the former by qPCR, multiple reference genes
or sequences on other chromosomes also need to be measured.
The qPCR results also reflect the average gene copy number
changes in DNA derived from thousands of microdissected tumour
cells, whereas only a relatively small fraction (50 to few hundreds)
of tumour cells are selected for FISH scoring. The poorer
correlation between qPCR and FISH in SQCC compared to ADC
could be due to the tendency of FISH to score tumour giant cells
(cells with multilobated nuclei or multiple fused nuclei) that
commonly contained multiple (5–10) copies of both hTERT and
5q reference loci; such giant tumour cells are more common in
SQCC compared to ADC. Their scores may skew the assessment of
gene copy number and introduce a higher variability in copy
number estimation. Thus, the inability of our FISH studies to
predict early recurrence of patients with hTERT gene amplification
could result from: (1) smaller number of patients studied by FISH
compared to qPCR, (2) cellular heterogeneity that skewed the
overall FISH score due to recently acquired amplification in a
discrete region within the tumour and (3) inconsistencies in FISH
signal scoring criteria associated with polyploid nuclei and
sectioning artefacts. Amplification has been defined differently in
various FISH studies, such as X3 (Murnane and Sabatier, 2004) or
X5 (Zhang et al, 2000) gene copies in at least 20% of the cells, or
presence of tight gene clusters and a ratio of gene to chromosome
of X2o rX15 copies of gene per cell in X10% of analysed cells
(Cappuzzo et al, 2005).
The reported frequencies of hTERT mRNA or protein over-
expression in NSCLC ranged from 33 to 94%. In general, RT–
qPCR data tended to demonstrate a higher overexpression rate
compared to immunohistochemistry or mRNA in situ hybridiza-
tion (mISH). Similar to our finding, most RT–qPCR studies but
not other methods have also detected trace hTERT mRNA
expression in normal lung tissues. We also found a correlation
between hTERT amplification and overexpression, but mainly
among the ADC.
The prognostic significance of hTERT expression or activity in
NSCLC remains controversial (Table 6). Such an association has
been reported in mISH (Kumaki et al, 2001; Wang et al, 2002;
Fujita et al, 2003; Lantuejoul et al, 2004) and immunohistochem-
istry studies (Kumaki et al, 2001; Toomey et al, 2001; Lantuejoul
et al, 2004). In contrast, the prognostic value of hTERT mRNA
expression assayed by RT–qPCR has been inconsistent (Komiya
et al, 2000; Hara et al, 2001; Marchetti et al, 2002; Wu et al, 2003;
Hsu et al, 2004). Some studies have associated overexpression with
poor prognosis (Komiya et al, 2000; Hara et al, 2001; Marchetti
et al, 2002; Hsu et al, 2004), while others have failed to do so
(Wu et al, 2003). One possible explanation is that hTERT mRNA
has six known splice variants, but only the full-length transcript is
functional. The qPCR probes designed in these studies did not
distinguish between these variants. Although full-length mRNA
level is usually proportional to the other variants (Fujiwara et al,
2004), it may range from 5 to 54% (Yi et al, 2001; Fujiwara et al,
2004). However, our finding that hTERT overexpression was
predictive of poorer overall survival at 3 years is in agreement with
a majority of these studies.
In conclusion, we have for the first time provided evidence that
hTERT gene amplification or high copy number could be a marker
for poorer prognosis in early-stage NSCLC patients, perhaps even
more reliably than hTERT overexpression. While the clinical
application of our findings requires more extensive retrospective
and prospective validations in additional and larger cohorts of
patients, further studies to evaluate the prognostic significance
of hTERT by FISH is also warranted. In such case, a more refined
FISH scoring system with reproducible criteria to identify
clinically and biologically valid hTERT gene amplification would
Table 6 Previous reports on the prognostic significance of telomerase
Prognostic significance
Case Activity
hTERT expression
(assay)
a TRFLR
b
Albanell et al (1997) 99 No — No
Taga et al (1999) 103 Yes — —
Komiya et al (2000) 68 — Yes (RT–qPCR) —
Hirashima et al (2000) 72 No — Yes
Arinaga et al (2000) 92 — No (RT–qPCR) —
Kumaki et al (2001) 115 Yes No (mISH, IHC) —
Hara et al (2001) 62 — Yes (RT–semi-qPCR) —
Toomey et al (2001) 115 — No (IHC) —
Wang et al (2002) 153 — Yes (mISH) —
Marchetti et al (2002) 90 Yes YES (RT–qPCR) —
Wu et al (2003) 56 Yes No (RT–qPCR) —
Fujita et al (2003) 146 — Yes (mISH) —
Hsu et al (2004) 48 No — Yes
Lantuejoul et al (2004) 122 — Yes (mISH, IHC) —
Lu et al (2004) 94 — No (mISH) —
a—¼not studied; RT–qPCR¼reverse transcription–quantitative polymerase chain
reaction; mISH¼mRNA in situ hybridisation; IHC¼immunohistochemistry.
bTelo-
mere terminal restriction fragment length ratio (tumour vs normal).
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cancer cells to avoid senescence (Shay and Roninson, 2004) and
the latter could be induced by chemotherapy, the predictive value
of hTERT amplification for benefit to adjuvant chemotherapy also
needs evaluation (Winton et al, 2005). Recently, telomerase has
been intensively studied as a target for novel cancer gene therapy
and therapeutics (reviewed in Shay and Wright, 2002; Keith et al,
2004). Our finding that different types of NSCLC may alternately
regulate hTERT overexpression suggests that patients with hTERT
amplification could have different responses to telomerase-based
therapies. The possible differential role of hTERT gene dosage in
the diagnosis and treatment of lung cancer patients should be
further investigated.
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